Literature DB >> 23205085

Lymphangiogenesis in non-Hodgkin's lymphoma and its correlation with cyclooxygenase-2 and vascular endothelial growth factor-C.

Shu-Pei Ma1, Mei Lin, Hai-Ning Liu, Jian-Xian Yu.   

Abstract

We aimed to investigate the correlations between lymphangiogenesis, cyclooxygenase (COX)-2 and vascular endothelial growth factor-C (VEGF-C) in non-Hodgkin's lymphoma (NHL) and their associations with the clinical parameters of patients. A total of 75 patients diagnosed with NHL were enrolled in this study. Of the 75 patients, 14 (18.7%) had low-grade and 61 (81.3%) had aggressive lymphoma. We examined the immunohistochemical expression of COX-2 and VEGF-C and estimated lymphangiogenesis by counting lymphatic vessels expressing lymph vessel endothelial hyaluronan receptor-1 (LYVE-1). Our results showed that lymphatic vessel density (LVD) was positive in 59.0% of the cases with aggressive morphology, while the LVD positive rate of indolent lymphoma was only 28.6% (P=0.039). Both COX-2 and VEGF-C were correlated with lymphangiogenesis (P=0.030 and 0.000, respectively). The expression levels of COX-2 and VEGF-C were significantly correlated (P=0.015). LVD, COX-2 and VEGF-C were not correlated with the gender, age, lactate dehydrogenase (LDH) levels, β2 microglobulin (β2M) levels, extranodal involvement, disease stage, B symptoms or international prognostic index of the patients. In conclusion, lymphangiogenesis was correlated with aggressive histology in NHL. COX-2 and VEGF-C are inducers of lymphangiogenesis and their expression levels were correlated in NHL.

Entities:  

Year:  2012        PMID: 23205085      PMCID: PMC3506712          DOI: 10.3892/ol.2012.817

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

Review 1.  Perspectives on lymphangiogenesis and angiogenesis in cancer.

Authors:  Tanja Holopainen; Maija Bry; Kari Alitalo; Anne Saaristo
Journal:  J Surg Oncol       Date:  2011-05-01       Impact factor: 3.454

Review 2.  Cyclooxygenase-1 and -2 isoenzymes.

Authors:  T Hla; D Bishop-Bailey; C H Liu; H J Schaefers; O C Trifan
Journal:  Int J Biochem Cell Biol       Date:  1999-05       Impact factor: 5.085

3.  Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes.

Authors:  Tomasz Wróel; Grzegorz Mazur; Piotr Dziegiel; Michał Jeleń; Andrzej Szuba; Kazimierz Kuliczkowski; Maciej Zabel
Journal:  Folia Histochem Cytobiol       Date:  2006       Impact factor: 1.698

4.  COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Dimitrios Stefanou; Niki J Agnantis
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

5.  Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.

Authors:  Dita Gratzinger; Shuchun Zhao; Robert J Marinelli; Amy V Kapp; Robert J Tibshirani; Anne S Hammer; Stephen Hamilton-Dutoit; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

6.  Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.

Authors:  Jen-Liang Su; Jin-Yuan Shih; Men-Luh Yen; Yung-Ming Jeng; Cheng-Chi Chang; Chang-Yao Hsieh; Lin-Hung Wei; Pan-Chyr Yang; Min-Liang Kuo
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

7.  The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients.

Authors:  Kristen N Ganjoo; Annette M Moore; Attilio Orazi; Joy A Sen; Cynthia S Johnson; Caroline S An
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-11       Impact factor: 4.553

8.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

9.  Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix.

Authors:  Adhemar Longatto-Filho; Céline Pinheiro; Sônia Maria Miranda Pereira; Daniela Etlinger; Marise A R Moreira; Luiz Fernando Jubé; Geraldo Silva Queiroz; Fátima Baltazar; Fernando C Schmitt
Journal:  Gynecol Oncol       Date:  2007-07-02       Impact factor: 5.482

10.  Digging deeper into lymphatic vessel formation in vitro and in vivo.

Authors:  Benoit Detry; Françoise Bruyère; Charlotte Erpicum; Jenny Paupert; Françoise Lamaye; Catherine Maillard; Bénédicte Lenoir; Jean-Michel Foidart; Marc Thiry; Agnès Noël
Journal:  BMC Cell Biol       Date:  2011-06-24       Impact factor: 4.241

View more
  4 in total

1.  Association of β2-microglobulin with the prognosis of non-Hodgkin's lymphoma: a meta analysis.

Authors:  Xiao-Liang Wang; Xiao-Li Wang; Shuo He; Hong-Li Zhai
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Podoplanin as a Predictive Marker for Identification of High-Risk Mycosis Fungoides Patients: An Immunohistochemical Study.

Authors:  Amal A El-Ashmawy; Maha M Shamloula; Nashwa N Elfar
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

3.  Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma.

Authors:  Jorge Castro-López; Antonio Ramis; Marta Planellas; Mariana Teles; Josep Pastor
Journal:  BMC Vet Res       Date:  2018-05-15       Impact factor: 2.741

4.  B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Authors:  Cinzia Giagulli; Francesca Caccuri; Simone Zorzan; Antonella Bugatti; Alberto Zani; Federica Filippini; Ekta Manocha; Pasqualina D'Ursi; Alessandro Orro; Riccardo Dolcetti; Arnaldo Caruso
Journal:  Cancer Gene Ther       Date:  2020-10-22       Impact factor: 5.987

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.